Gilead Sciences GILD
NASDAQ GILD
$143.72 -1.09 (-0.75%)
As of: Sep 11, 2026 · 3:59 PM EDT

Gilead Sciences (GILD) Goodwill & Intangibles (2009 - 2026)

Gilead Sciences' (GILD) quarterly Goodwill & Intangibles came in at $22.3 billion in Q2 2026, down 16.87% on a YoY basis from $26.9 billion in Q2 2025, and down 9.52% quarter-over-quarter from $24.7 billion in Q1 2026.

Analysis

Gilead Sciences (GILD) Goodwill & Intangibles (2009 - 2026) Analysis & Trends

Gilead Sciences (GILD) has reported Goodwill & Intangibles for 18 consecutive years, with $22.3 billion the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Goodwill & Intangibles fell 16.87% year-over-year to $22.3 billion; the trailing twelve-month figure through Jun 2026 stood at $22.3 billion (down 16.87% YoY), and the FY2025 full-year result was $25.3 billion, down 10.51% from the prior year.
  • Goodwill & Intangibles fell to $22.3 billion in Q2 2026 per GILD's latest filing, from $24.7 billion in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $38.6 billion in Q1 2022 and bottomed at $22.3 billion in Q2 2026.
  • Historically, Goodwill & Intangibles has averaged $31.6 billion across 5 years, with a median of $31.4 billion in 2024.
  • The sharpest annual moves came in 2023 and 2024: Goodwill & Intangibles slipped 5.13% in 2023, then fell 18.71% in 2024.
  • Over 5 years, Goodwill & Intangibles stood at $37.2 billion in 2022, then retreated by 6.56% to $34.8 billion in 2023, then dropped by 18.71% to $28.3 billion in 2024, then dropped by 10.51% to $25.3 billion in 2025, then slipped by 11.65% to $22.3 billion in 2026.
  • According to Business Quant data, Goodwill & Intangibles over the past three periods registered $22.3 billion, $24.7 billion, and $25.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn
10 Insmed 28.06 Bn 26.90 Bn 358.27 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 22.35 Bn
Mar 31, 2026 24.70 Bn
Dec 31, 2025 25.29 Bn
Sep 30, 2025 26.28 Bn
Jun 30, 2025 26.88 Bn
Mar 31, 2025 27.67 Bn
Dec 31, 2024 28.26 Bn
Sep 30, 2024 28.86 Bn
Jun 30, 2024 31.15 Bn
Mar 31, 2024 31.74 Bn
Dec 31, 2023 34.77 Bn
Sep 30, 2023 35.47 Bn
Jun 30, 2023 36.06 Bn
Mar 31, 2023 36.66 Bn
Dec 31, 2022 37.21 Bn
Sep 30, 2022 37.75 Bn
Jun 30, 2022 38.20 Bn
Mar 31, 2022 38.65 Bn
Dec 31, 2021 41.79 Bn
Sep 30, 2021 42.23 Bn